ATC Φάρμακα Δραστικές ICPC2 ICD10 Ιατρική στην Πράξη Νοσήματα Λοιμώξεις Εμβόλια Πρωτόκολλα
  • Arsenic trioxide
  • indication:For induction of remission and consolidation in patients with acute promyelocytic leukemia (APL), and whose APL is characterized by the presence of the t(15;17) translocation or PML/RAR-alpha gene expression
  • pharmacologypharmacology:
  • mechanism: The mechanism of action of Arsenic Trioxide is not completely understood. Arsenic trioxide causes morphological changes and DNA fragmentation characteristic of apoptosis in NB4 human promyelocytic leukemia cells <i>in vitro</i>. Arsenic trioxide also causes damage or degradation of the fusion protein PML/RAR-alpha. It is suspected that arsenic trioxide induces cancer cells to undergo apoptosis.
  • toxicity: Symptoms of overdose include convulsions, muscle weakness and confusion.
  • absorprion:
  • halflife:
  • roouteelimination: Trivalent arsenic is mostly methylated in humans and excreted in urine.
  • volumedistribution:
  • clearance: